{"gene":"PDE9A","run_date":"2026-06-10T05:19:53","timeline":{"discoveries":[{"year":1998,"finding":"PDE9A encodes a cGMP-specific phosphodiesterase with a Km of 170 nM for cGMP (one of the highest affinities among known PDEs) and ~230 µM for cAMP, with Vmax ~4.9 nmol/min/µg; the enzyme is insensitive to classic PDE inhibitors (rolipram, IBMX, dipyridamole) but inhibited by zaprinast (IC50 ~35 µM); activity is approximately twice as high in 1–10 mM Mn²⁺ as in Mg²⁺ or Ca²⁺; PDE9A lacks allosteric cGMP-binding regulatory regions present in PDE2, PDE5, and PDE6.","method":"Baculovirus expression of FLAG-tagged full-length PDE9A; radiometric kinetic enzyme assays; inhibitor panel testing in vitro","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct in vitro reconstitution with kinetic analysis and inhibitor profiling; foundational characterization replicated across labs","pmids":["9624146"],"is_preprint":false},{"year":1998,"finding":"PDE9A pre-mRNA is alternatively spliced into at least four variants (PDE9A1–A4) that differ at their 5′ exons, altering the N-terminal amino acid sequences while retaining the conserved catalytic domain; the gene spans ~122 kb and comprises 20 exons; the human and mouse orthologs share 93% amino acid identity.","method":"cDNA cloning, genomic sequencing, Northern blot, comparison of human and mouse cDNAs","journal":"Human genetics","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct cDNA/genomic sequencing with orthogonal Northern blot; independently consistent with PMID 9624146","pmids":["9856478"],"is_preprint":false},{"year":2003,"finding":"PDE9A1 localizes exclusively to the nucleus of HEK293 cells and native T cells, dependent on a unique pat7 nuclear localization motif in its N-terminal extension, whereas PDE9A5 (a new splice variant lacking exons 2 and 5) localizes exclusively to the cytoplasm; both variants show similar high-affinity cGMP hydrolysis (Km ~0.25–0.39 µM) but different Vmax values.","method":"Transient transfection of HEK293 cells, subcellular fractionation, Western blot of T-cell nuclear/cytoplasmic fractions, kinetic enzyme assays, real-time quantitative PCR","journal":"Gene","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal fractionation/Western blot + functional kinetics + multiple orthogonal methods in one study","pmids":["14527714"],"is_preprint":false},{"year":2018,"finding":"PDE9A localizes to the membrane fraction in brain (and most organs) and also to the nuclear fraction in brain; isoform PDE9A2 predominates in non-brain tissues, while PDE9A6 and novel isoforms (PDE9X-100, PDE9X-120, PDE9X-175) are the predominant brain forms; subcellular compartmentalization is isoform-specific and brain-region-specific and changes with age.","method":"Subcellular fractionation of mouse and human brain tissue, isoform-specific detection, mRNA expression profiling across neurodevelopment","journal":"Neurobiology of aging","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct fractionation experiments with isoform-level resolution; single lab with multiple tissues and ages","pmids":["29505961"],"is_preprint":false},{"year":2014,"finding":"PDE9A is expressed in GABA-positive and GABA-negative amacrine cells and likely in certain ganglion cells of the inner retina; genetic knockout (PDE9A−/−) specifically prolongs and slows the photopic (cone pathway) ERG b-wave recovery without affecting scotopic responses, indicating PDE9A controls cGMP levels that modulate inhibitory processing within the cone pathway.","method":"LacZ reporter knock-in as PDE9A expression reporter, immunofluorescence, electroretinography in PDE9A knockout mice","journal":"Frontiers in molecular neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean KO with defined photopic ERG phenotype plus reporter-based localization; single lab","pmids":["25018695"],"is_preprint":false},{"year":2018,"finding":"PDE9A hydrolyzes the non-canonical cyclic nucleotide cUMP with low affinity (Km ~401 µM) and high velocity (Vmax ~6 µmol/min/mg); docking studies identify H-bonds between the cUMP uridine moiety and Gln453/Asn405 (versus three H-bonds for cGMP guanosine moiety with Gln453), explaining substrate selectivity via a glutamine-switch mechanism; BAY 73-6691 inhibits cUMP hydrolysis with Ki ~590 nM.","method":"HPLC-coupled tandem mass spectrometry kinetic assay, computational docking to PDE9A crystal structure","journal":"Naunyn-Schmiedeberg's archives of pharmacology","confidence":"Medium","confidence_rationale":"Tier 1–2 / Weak — direct enzymatic kinetics with MS detection plus structural docking; single lab, docking is computational","pmids":["30443663"],"is_preprint":false},{"year":2025,"finding":"The E3 ubiquitin ligase CHIP directly binds PDE9A, polyubiquitinates it, and targets it for autophagic degradation; loss-of-function CHIP mutations cause PDE9A accumulation, elevated cGMP hydrolysis, and impaired PKG phosphorylation of CHIP at Ser19; elevated PKA further inhibits PDE9A degradation; pharmacological PDE9A inhibition (BAY 73-6691) or virus-mediated CHIP restoration rescues mitophagy and reduces Purkinje neuron apoptosis in a CHIP-ataxia rodent model.","method":"Co-immunoprecipitation, polyubiquitination assays, preclinical rodent ataxia model, viral CHIP delivery, pharmacological inhibition, PKG/PKA phosphorylation readouts","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP, ubiquitination assay, genetic and pharmacological rescue, multiple orthogonal methods in one study","pmids":["39806097"],"is_preprint":false},{"year":2025,"finding":"NEURL1 (a RING-domain E3 ubiquitin ligase) promotes ubiquitination and proteasomal degradation of PDE9A in bladder cancer cells; RING-domain deletion of NEURL1 abolishes this effect; proteasome inhibitor MG-132 reverses NEURL1-induced PDE9A loss, confirming proteasomal targeting.","method":"Stable overexpression of WT and RING-deleted NEURL1 in 5637/RT-112 bladder cancer cells, Western blot, MG-132 rescue experiment, cell viability and apoptosis assays with PDE9A knockdown","journal":"In vitro cellular & developmental biology. Animal","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — direct ubiquitination/proteasome rescue experiment in cell lines; single lab, no in vitro reconstitution","pmids":["40442542"],"is_preprint":false},{"year":2017,"finding":"PDE9A expression is upregulated during cardiac hypertrophy; PDE9A knockdown alleviates phenylephrine-induced hypertrophic responses in neonatal rat cardiomyocytes; PDE9A inhibition elevates intracellular cGMP, increases phospholamban (PLB) phosphorylation, and upregulates SERCA2a expression in cardiomyocytes and in an ISO-induced heart failure rat model.","method":"siRNA knockdown, pharmacological inhibition with C33(S) and PF-7943 in neonatal rat cardiomyocytes, in vivo rat heart failure model (ISO/AAC), echocardiography, cGMP measurement, Western blot","journal":"Acta pharmacologica Sinica","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic (siRNA) and pharmacological loss-of-function with defined molecular readouts; single lab, multiple orthogonal approaches","pmids":["28649129"],"is_preprint":false},{"year":2015,"finding":"PDE9A inhibition (BAY73-6691) significantly increases gamma-globin (HBG) gene expression in K562 erythroleukaemic cells and reverses the elevated adhesive properties of sickle cell disease neutrophils, consistent with PDE9A controlling cGMP levels in haematopoietic cells.","method":"Pharmacological inhibition with BAY73-6691 in K562 cells and primary SCD neutrophils; gene expression analysis; adhesion assay","journal":"British journal of haematology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — pharmacological loss-of-function with defined cellular phenotypes; single lab, no genetic complementation","pmids":["18564357"],"is_preprint":false},{"year":2015,"finding":"PDE9A inhibition (but not PDE2A inhibition) did not alter paired-pulse facilitation (PPF) in rat hippocampal CA1 slices, indicating PDE9A does not modulate presynaptic short-term plasticity under tested conditions, in contrast to PDE2A which acts presynaptically.","method":"Paired-pulse facilitation electrophysiology in acute rat hippocampal slices with selective PDE9A inhibitors","journal":"Synapse (New York, N.Y.)","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — this is a NEGATIVE finding, explicitly established by direct electrophysiological assay; single lab","pmids":["26178667"],"is_preprint":false},{"year":2020,"finding":"In zebrafish oocytes, PDE9a maintains meiotic arrest by sustaining basal cGMP levels; overexpression of pde9aa mRNA in oocytes decreased cGMP and stimulated meiotic maturation, while PDE9a inhibition (BAY736691) also stimulated maturation via a gap-junction-dependent mechanism (blocking gap junctions abolished the effect); the stimulatory effect of elevated PDE9a during LH-induced maturation operates through oocyte cGMP hydrolysis.","method":"mRNA injection into zebrafish oocytes, cGMP measurement, pharmacological inhibition with BAY736691, gap junction blocker experiments, in vitro fertilization","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain-of-function mRNA injection plus pharmacological inhibition with gap-junction epistasis; single lab, zebrafish ortholog","pmids":["32826058"],"is_preprint":false},{"year":2021,"finding":"PDE9A deficiency (Pde9a−/− mice) does not prevent chronic-hypoxic pulmonary hypertension; RV pressure, hypertrophy, and cGMP levels were not different between Pde9a−/− and wild-type mice after 3 weeks of hypoxic exposure, indicating PDE9A does not play a prominent role in the murine CH-PH model (in contrast to its established role in left ventricular pressure overload).","method":"Pde9a knockout mice, chronic hypoxia model, RV pressure measurement, cGMP quantification, VASP phosphorylation Western blot","journal":"Physiological reports","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — NEGATIVE finding established by clean KO with defined physiological and biochemical readouts; single lab","pmids":["34569183"],"is_preprint":false}],"current_model":"PDE9A is a high-affinity, cGMP-specific phosphodiesterase (Km ~170 nM for cGMP) that exists in multiple alternatively spliced isoforms with distinct subcellular localizations—PDE9A1 is nuclear (via a pat7 NLS), PDE9A5 is cytoplasmic, and brain isoforms associate with membranes and nuclear fractions—and its protein level is regulated by at least two E3 ubiquitin ligases (CHIP and NEURL1) that polyubiquitinate PDE9A for autophagic or proteasomal degradation; by controlling compartment-specific cGMP pools, PDE9A modulates PKG-dependent signaling in cardiomyocytes (affecting phospholamban/SERCA2a), inhibitory processing in the cone pathway of the retina, cGMP-dependent meiotic arrest in oocytes, and haematopoietic cell function, while its inhibition is cardioprotective in left ventricular pressure overload but not in right ventricular hypoxic hypertension."},"narrative":{"mechanistic_narrative":"PDE9A is a high-affinity, cGMP-specific phosphodiesterase (Km ~170 nM for cGMP) that shapes compartment-specific cGMP pools across multiple tissues [PMID:9624146]. It hydrolyzes cGMP with selectivity over cAMP, lacks the allosteric cGMP-binding regulatory regions found in PDE2/5/6, and is insensitive to classic PDE inhibitors while being blocked by zaprinast; substrate discrimination at the catalytic site operates through a glutamine-switch involving Gln453 [PMID:9624146, PMID:30443663]. The gene is alternatively spliced into isoforms that differ only in their N-terminal extensions, and these N-termini dictate subcellular targeting: PDE9A1 is nuclear via a pat7 NLS while PDE9A5 is cytoplasmic, and brain isoforms partition between membrane and nuclear fractions in an age- and region-specific manner [PMID:9856478, PMID:14527714, PMID:29505961]. PDE9A protein abundance is set by ubiquitin-dependent turnover through two E3 ligases—CHIP, which polyubiquitinates PDE9A for autophagic degradation, and NEURL1, which targets it for proteasomal degradation [PMID:39806097, PMID:40442542]. Through control of local cGMP/PKG signaling, PDE9A modulates cardiomyocyte hypertrophy via the phospholamban/SERCA2a axis [PMID:28649129], inhibitory processing in the retinal cone pathway [PMID:25018695], cGMP-dependent meiotic arrest in oocytes [PMID:32826058], and haematopoietic cell function [PMID:18564357]; its inhibition is beneficial in left ventricular pressure overload but not in chronic-hypoxic pulmonary hypertension [PMID:28649129, PMID:34569183].","teleology":[{"year":1998,"claim":"Established the core catalytic identity of PDE9A as the highest-affinity cGMP phosphodiesterase known, distinguishing it from other PDEs by inhibitor profile and absence of allosteric regulatory domains.","evidence":"Baculovirus expression of FLAG-tagged PDE9A with radiometric kinetics and inhibitor panel testing in vitro","pmids":["9624146"],"confidence":"High","gaps":["No structural basis for cGMP selectivity resolved at this stage","Physiological cGMP source and downstream effectors not addressed"]},{"year":1998,"claim":"Defined the gene architecture and alternative splicing that generates isoforms differing only in N-terminal sequence, framing how a single catalytic enzyme could be diversified functionally.","evidence":"cDNA cloning, genomic sequencing and Northern blot across human and mouse","pmids":["9856478"],"confidence":"High","gaps":["Functional consequence of distinct N-termini not yet tested","Isoform-specific expression patterns unresolved"]},{"year":2003,"claim":"Showed that the spliced N-terminal extensions act as localization signals, explaining how PDE9A isoforms partition cGMP hydrolysis between nucleus and cytoplasm.","evidence":"Transfection, reciprocal subcellular fractionation/Western blot and kinetic assays in HEK293 and T cells","pmids":["14527714"],"confidence":"High","gaps":["Compartment-specific cGMP substrate pools not directly measured","In vivo relevance of nuclear vs cytoplasmic targeting unestablished"]},{"year":2014,"claim":"Connected PDE9A to a specific neural circuit function by showing knockout selectively alters cone-pathway ERG recovery, identifying a role in retinal inhibitory processing.","evidence":"LacZ reporter knock-in, immunofluorescence and electroretinography in PDE9A knockout mice","pmids":["25018695"],"confidence":"Medium","gaps":["Downstream PKG targets in amacrine/ganglion cells not identified","Mechanism linking cGMP to inhibitory processing not resolved"]},{"year":2008,"claim":"Implicated PDE9A in haematopoietic cell biology by showing inhibition induces gamma-globin and reverses sickle-cell neutrophil adhesion.","evidence":"Pharmacological inhibition (BAY73-6691) in K562 cells and SCD neutrophils with gene expression and adhesion assays","pmids":["18564357"],"confidence":"Medium","gaps":["No genetic confirmation of target specificity","cGMP effector pathway in these cells undefined"]},{"year":2015,"claim":"Distinguished PDE9A from PDE2A in synaptic physiology by demonstrating PDE9A inhibition does not affect presynaptic short-term plasticity.","evidence":"Paired-pulse facilitation electrophysiology in rat hippocampal slices with selective inhibitors","pmids":["26178667"],"confidence":"Medium","gaps":["Negative result; postsynaptic or other plasticity roles not excluded","Single lab, conditions-limited"]},{"year":2017,"claim":"Linked PDE9A to cardiac hypertrophy through the cGMP–PKG–phospholamban/SERCA2a axis, establishing a cardioprotective rationale for inhibition.","evidence":"siRNA knockdown and pharmacological inhibition in cardiomyocytes plus an in vivo rat heart failure model with cGMP and Western blot readouts","pmids":["28649129"],"confidence":"Medium","gaps":["Which PDE9A isoform mediates the cardiac pool not defined","Direct PKG-PDE9A spatial coupling not shown"]},{"year":2018,"claim":"Resolved isoform-specific and brain-region-specific subcellular distribution, showing PDE9A compartmentalization changes across neurodevelopment and aging.","evidence":"Subcellular fractionation of mouse and human brain with isoform-specific detection and developmental mRNA profiling","pmids":["29505961"],"confidence":"Medium","gaps":["Functional output of novel brain isoforms unknown","Membrane-association mechanism not defined"]},{"year":2018,"claim":"Extended PDE9A substrate scope to the non-canonical cyclic nucleotide cUMP and provided a structural glutamine-switch explanation for nucleotide selectivity.","evidence":"HPLC-tandem MS kinetic assays with computational docking to the PDE9A crystal structure","pmids":["30443663"],"confidence":"Medium","gaps":["Physiological role of cUMP hydrolysis unestablished","Docking model not validated by mutagenesis"]},{"year":2020,"claim":"Defined a reproductive function for PDE9A in maintaining oocyte meiotic arrest through gap-junction-dependent cGMP control.","evidence":"mRNA injection and pharmacological inhibition in zebrafish oocytes with cGMP measurement and gap-junction epistasis","pmids":["32826058"],"confidence":"Medium","gaps":["Mammalian oocyte relevance not tested","Source of the cGMP pool not pinpointed"]},{"year":2021,"claim":"Delineated the limits of PDE9A's cardiopulmonary role by showing knockout does not prevent chronic-hypoxic pulmonary hypertension, contrasting with left ventricular pressure overload.","evidence":"Pde9a knockout mice in a chronic hypoxia model with RV pressure, cGMP and VASP phosphorylation readouts","pmids":["34569183"],"confidence":"Medium","gaps":["Negative result; mechanism of context-dependence unexplained","Compensatory PDE activity not assessed"]},{"year":2025,"claim":"Identified ubiquitin-dependent control of PDE9A abundance by two distinct E3 ligases, defining how PDE9A protein levels—and thus cGMP/PKG signaling—are set, with therapeutic relevance in CHIP-ataxia and bladder cancer.","evidence":"Co-IP, polyubiquitination assays, RING-domain mutants, MG-132 and pharmacological/viral rescue across a rodent ataxia model and bladder cancer cell lines","pmids":["39806097","40442542"],"confidence":"High","gaps":["Whether CHIP and NEURL1 target the same isoforms or compartments unknown","Crosstalk between autophagic and proteasomal routes not resolved","PKG/PKA phosphorylation feedback on degradation mapped only in CHIP context"]},{"year":null,"claim":"It remains unknown how the distinct localized cGMP pools generated by individual PDE9A isoforms are coupled to specific PKG effectors across tissues, and how ubiquitin-dependent turnover is coordinated with this spatial control.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No isoform-resolved mapping of cGMP microdomains to effectors","Integration of E3-ligase regulation with subcellular targeting unexplored"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,2,5]},{"term_id":"GO:0140098","term_label":"catalytic activity, acting on RNA","supporting_discovery_ids":[0,5]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[2,3]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[2]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[3]}],"pathway":[],"complexes":[],"partners":["STUB1","NEURL1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O76083","full_name":"High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A","aliases":[],"length_aa":593,"mass_kda":68.5,"function":"Specifically hydrolyzes the second messenger cGMP, which is a key regulator of many important physiological processes. Highly specific: compared to other members of the cyclic nucleotide phosphodiesterase family, has the highest affinity and selectivity for cGMP (PubMed:18757755, PubMed:21483814, PubMed:9624146). Specifically regulates natriuretic-peptide-dependent cGMP signaling in heart, acting as a regulator of cardiac hypertrophy in myocytes and muscle. Does not regulate nitric oxide-dependent cGMP in heart (PubMed:25799991). Additional experiments are required to confirm whether its ability to hydrolyze natriuretic-peptide-dependent cGMP is specific to heart or is a general feature of the protein (Probable). In brain, involved in cognitive function, such as learning and long-term memory (By similarity)","subcellular_location":"Cytoplasm; Endoplasmic reticulum","url":"https://www.uniprot.org/uniprotkb/O76083/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PDE9A","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PDE9A","total_profiled":1310},"omim":[{"mim_id":"602973","title":"PHOSPHODIESTERASE 9A; PDE9A","url":"https://www.omim.org/entry/602973"},{"mim_id":"602184","title":"NADH-UBIQUINONE OXIDOREDUCTASE FLAVOPROTEIN 3; NDUFV3","url":"https://www.omim.org/entry/602184"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Cytosol","reliability":"Supported"},{"location":"Nucleoplasm","reliability":"Additional"},{"location":"Plasma membrane","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"intestine","ntpm":69.9}],"url":"https://www.proteinatlas.org/search/PDE9A"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"O76083","domains":[{"cath_id":"3.10.20,3.10.20","chopping":"12-81","consensus_level":"high","plddt":86.4323,"start":12,"end":81},{"cath_id":"1.10.1300.10","chopping":"251-480","consensus_level":"high","plddt":96.6427,"start":251,"end":480}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O76083","model_url":"https://alphafold.ebi.ac.uk/files/AF-O76083-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O76083-F1-predicted_aligned_error_v6.png","plddt_mean":81.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PDE9A","jax_strain_url":"https://www.jax.org/strain/search?query=PDE9A"},"sequence":{"accession":"O76083","fasta_url":"https://rest.uniprot.org/uniprotkb/O76083.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O76083/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O76083"}},"corpus_meta":[{"pmid":"9624146","id":"PMC_9624146","title":"Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9624146","citation_count":301,"is_preprint":false},{"pmid":"14527714","id":"PMC_14527714","title":"Identification and characterization of a new human type 9 cGMP-specific phosphodiesterase splice variant (PDE9A5). Differential tissue distribution and subcellular localization of PDE9A variants.","date":"2003","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/14527714","citation_count":67,"is_preprint":false},{"pmid":"24801218","id":"PMC_24801218","title":"A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer's disease.","date":"2014","source":"Current Alzheimer research","url":"https://pubmed.ncbi.nlm.nih.gov/24801218","citation_count":65,"is_preprint":false},{"pmid":"22780914","id":"PMC_22780914","title":"Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disorders.","date":"2012","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22780914","citation_count":51,"is_preprint":false},{"pmid":"9856478","id":"PMC_9856478","title":"Identification and characterization of a novel cyclic nucleotide phosphodiesterase gene (PDE9A) that maps to 21q22.3: alternative splicing of mRNA transcripts, genomic structure and sequence.","date":"1998","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9856478","citation_count":47,"is_preprint":false},{"pmid":"26178667","id":"PMC_26178667","title":"Inhibition of PDE2A, but not PDE9A, modulates presynaptic short-term plasticity measured by paired-pulse facilitation in the CA1 region of the hippocampus.","date":"2015","source":"Synapse (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/26178667","citation_count":31,"is_preprint":false},{"pmid":"29505961","id":"PMC_29505961","title":"Identification of new PDE9A isoforms and how their expression and subcellular compartmentalization in the brain change across the life span.","date":"2018","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/29505961","citation_count":30,"is_preprint":false},{"pmid":"18564357","id":"PMC_18564357","title":"High expression of the cGMP-specific phosphodiesterase, PDE9A, in sickle cell disease (SCD) and the effects of its inhibition in erythroid cells and SCD neutrophils.","date":"2008","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/18564357","citation_count":26,"is_preprint":false},{"pmid":"28649129","id":"PMC_28649129","title":"C33(S), a novel PDE9A inhibitor, protects against rat cardiac hypertrophy through upregulating cGMP signaling.","date":"2017","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/28649129","citation_count":23,"is_preprint":false},{"pmid":"27676442","id":"PMC_27676442","title":"Reversal of neurobehavioral social deficits in dystrophic mice using inhibitors of phosphodiesterases PDE5A and PDE9A.","date":"2016","source":"Translational psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/27676442","citation_count":16,"is_preprint":false},{"pmid":"26556348","id":"PMC_26556348","title":"Validation of PDE9A Gene Identified in GWAS Showing Strong Association with Milk Production Traits in Chinese Holstein.","date":"2015","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/26556348","citation_count":14,"is_preprint":false},{"pmid":"19445908","id":"PMC_19445908","title":"PDE9A, PDE10A, and PDE11A expression in rat trigeminovascular pain signalling system.","date":"2009","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/19445908","citation_count":12,"is_preprint":false},{"pmid":"25018695","id":"PMC_25018695","title":"PDE9A is expressed in the inner retina and contributes to the normal shape of the photopic ERG waveform.","date":"2014","source":"Frontiers in molecular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/25018695","citation_count":12,"is_preprint":false},{"pmid":"31548916","id":"PMC_31548916","title":"LY86, LRG1 and PDE9A genes overexpression in umbilical cord blood hematopoietic stem progenitor cells by acute myeloid leukemia (M3) microvesicles.","date":"2019","source":"Experimental hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31548916","citation_count":8,"is_preprint":false},{"pmid":"36475653","id":"PMC_36475653","title":"BAY-7081: A Potent, Selective, and Orally Bioavailable Cyanopyridone-Based PDE9A Inhibitor.","date":"2022","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/36475653","citation_count":7,"is_preprint":false},{"pmid":"30443663","id":"PMC_30443663","title":"Hydrolysis of the non-canonical cyclic nucleotide cUMP by PDE9A: kinetics and binding mode.","date":"2018","source":"Naunyn-Schmiedeberg's archives of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30443663","citation_count":6,"is_preprint":false},{"pmid":"39806097","id":"PMC_39806097","title":"E3 ubiquitin ligase CHIP facilitates cAMP and cGMP signalling cross-talk by polyubiquitinating PDE9A.","date":"2025","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/39806097","citation_count":5,"is_preprint":false},{"pmid":"34569183","id":"PMC_34569183","title":"PDE9A deficiency does not prevent chronic-hypoxic pulmonary hypertension in mice.","date":"2021","source":"Physiological reports","url":"https://pubmed.ncbi.nlm.nih.gov/34569183","citation_count":5,"is_preprint":false},{"pmid":"39325678","id":"PMC_39325678","title":"PDE9A Inhibition Improves Coronary Microvascular Rarefaction and Left Ventricular Diastolic Dysfunction in the ZSF1 Rat Model of HFpEF.","date":"2024","source":"Microcirculation (New York, N.Y. : 1994)","url":"https://pubmed.ncbi.nlm.nih.gov/39325678","citation_count":5,"is_preprint":false},{"pmid":"32826058","id":"PMC_32826058","title":"Dual roles of PDE9a in meiotic maturation of zebrafish oocytes.","date":"2020","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/32826058","citation_count":2,"is_preprint":false},{"pmid":"38184018","id":"PMC_38184018","title":"PDE9A polymorphism and association analysis with growth performance and gastrointestinal weight of Hu sheep.","date":"2024","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/38184018","citation_count":1,"is_preprint":false},{"pmid":"40650137","id":"PMC_40650137","title":"PDE9A Promotes Calcium-Handling Dysfunction in Right Heart Failure via cGMP-PKG Pathway Suppression: A Mechanistic and Therapeutic Review.","date":"2025","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/40650137","citation_count":1,"is_preprint":false},{"pmid":"40442542","id":"PMC_40442542","title":"NEURL1 acts as a candidate suppressor in bladder cancer by down-regulating PDE9A.","date":"2025","source":"In vitro cellular & developmental biology. Animal","url":"https://pubmed.ncbi.nlm.nih.gov/40442542","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":14512,"output_tokens":3686,"usd":0.049413,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":11436,"output_tokens":3692,"usd":0.07474,"stage2_stop_reason":"end_turn"},"total_usd":0.124153,"stage1_batch_id":"msgbatch_013a8chtv3AWyTqv4z4sEF4C","stage2_batch_id":"msgbatch_01AHsuW63vinsvuTgzmQ3n62","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1998,\n      \"finding\": \"PDE9A encodes a cGMP-specific phosphodiesterase with a Km of 170 nM for cGMP (one of the highest affinities among known PDEs) and ~230 µM for cAMP, with Vmax ~4.9 nmol/min/µg; the enzyme is insensitive to classic PDE inhibitors (rolipram, IBMX, dipyridamole) but inhibited by zaprinast (IC50 ~35 µM); activity is approximately twice as high in 1–10 mM Mn²⁺ as in Mg²⁺ or Ca²⁺; PDE9A lacks allosteric cGMP-binding regulatory regions present in PDE2, PDE5, and PDE6.\",\n      \"method\": \"Baculovirus expression of FLAG-tagged full-length PDE9A; radiometric kinetic enzyme assays; inhibitor panel testing in vitro\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct in vitro reconstitution with kinetic analysis and inhibitor profiling; foundational characterization replicated across labs\",\n      \"pmids\": [\"9624146\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"PDE9A pre-mRNA is alternatively spliced into at least four variants (PDE9A1–A4) that differ at their 5′ exons, altering the N-terminal amino acid sequences while retaining the conserved catalytic domain; the gene spans ~122 kb and comprises 20 exons; the human and mouse orthologs share 93% amino acid identity.\",\n      \"method\": \"cDNA cloning, genomic sequencing, Northern blot, comparison of human and mouse cDNAs\",\n      \"journal\": \"Human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct cDNA/genomic sequencing with orthogonal Northern blot; independently consistent with PMID 9624146\",\n      \"pmids\": [\"9856478\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"PDE9A1 localizes exclusively to the nucleus of HEK293 cells and native T cells, dependent on a unique pat7 nuclear localization motif in its N-terminal extension, whereas PDE9A5 (a new splice variant lacking exons 2 and 5) localizes exclusively to the cytoplasm; both variants show similar high-affinity cGMP hydrolysis (Km ~0.25–0.39 µM) but different Vmax values.\",\n      \"method\": \"Transient transfection of HEK293 cells, subcellular fractionation, Western blot of T-cell nuclear/cytoplasmic fractions, kinetic enzyme assays, real-time quantitative PCR\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal fractionation/Western blot + functional kinetics + multiple orthogonal methods in one study\",\n      \"pmids\": [\"14527714\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"PDE9A localizes to the membrane fraction in brain (and most organs) and also to the nuclear fraction in brain; isoform PDE9A2 predominates in non-brain tissues, while PDE9A6 and novel isoforms (PDE9X-100, PDE9X-120, PDE9X-175) are the predominant brain forms; subcellular compartmentalization is isoform-specific and brain-region-specific and changes with age.\",\n      \"method\": \"Subcellular fractionation of mouse and human brain tissue, isoform-specific detection, mRNA expression profiling across neurodevelopment\",\n      \"journal\": \"Neurobiology of aging\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct fractionation experiments with isoform-level resolution; single lab with multiple tissues and ages\",\n      \"pmids\": [\"29505961\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"PDE9A is expressed in GABA-positive and GABA-negative amacrine cells and likely in certain ganglion cells of the inner retina; genetic knockout (PDE9A−/−) specifically prolongs and slows the photopic (cone pathway) ERG b-wave recovery without affecting scotopic responses, indicating PDE9A controls cGMP levels that modulate inhibitory processing within the cone pathway.\",\n      \"method\": \"LacZ reporter knock-in as PDE9A expression reporter, immunofluorescence, electroretinography in PDE9A knockout mice\",\n      \"journal\": \"Frontiers in molecular neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean KO with defined photopic ERG phenotype plus reporter-based localization; single lab\",\n      \"pmids\": [\"25018695\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"PDE9A hydrolyzes the non-canonical cyclic nucleotide cUMP with low affinity (Km ~401 µM) and high velocity (Vmax ~6 µmol/min/mg); docking studies identify H-bonds between the cUMP uridine moiety and Gln453/Asn405 (versus three H-bonds for cGMP guanosine moiety with Gln453), explaining substrate selectivity via a glutamine-switch mechanism; BAY 73-6691 inhibits cUMP hydrolysis with Ki ~590 nM.\",\n      \"method\": \"HPLC-coupled tandem mass spectrometry kinetic assay, computational docking to PDE9A crystal structure\",\n      \"journal\": \"Naunyn-Schmiedeberg's archives of pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Weak — direct enzymatic kinetics with MS detection plus structural docking; single lab, docking is computational\",\n      \"pmids\": [\"30443663\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"The E3 ubiquitin ligase CHIP directly binds PDE9A, polyubiquitinates it, and targets it for autophagic degradation; loss-of-function CHIP mutations cause PDE9A accumulation, elevated cGMP hydrolysis, and impaired PKG phosphorylation of CHIP at Ser19; elevated PKA further inhibits PDE9A degradation; pharmacological PDE9A inhibition (BAY 73-6691) or virus-mediated CHIP restoration rescues mitophagy and reduces Purkinje neuron apoptosis in a CHIP-ataxia rodent model.\",\n      \"method\": \"Co-immunoprecipitation, polyubiquitination assays, preclinical rodent ataxia model, viral CHIP delivery, pharmacological inhibition, PKG/PKA phosphorylation readouts\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP, ubiquitination assay, genetic and pharmacological rescue, multiple orthogonal methods in one study\",\n      \"pmids\": [\"39806097\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"NEURL1 (a RING-domain E3 ubiquitin ligase) promotes ubiquitination and proteasomal degradation of PDE9A in bladder cancer cells; RING-domain deletion of NEURL1 abolishes this effect; proteasome inhibitor MG-132 reverses NEURL1-induced PDE9A loss, confirming proteasomal targeting.\",\n      \"method\": \"Stable overexpression of WT and RING-deleted NEURL1 in 5637/RT-112 bladder cancer cells, Western blot, MG-132 rescue experiment, cell viability and apoptosis assays with PDE9A knockdown\",\n      \"journal\": \"In vitro cellular & developmental biology. Animal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — direct ubiquitination/proteasome rescue experiment in cell lines; single lab, no in vitro reconstitution\",\n      \"pmids\": [\"40442542\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"PDE9A expression is upregulated during cardiac hypertrophy; PDE9A knockdown alleviates phenylephrine-induced hypertrophic responses in neonatal rat cardiomyocytes; PDE9A inhibition elevates intracellular cGMP, increases phospholamban (PLB) phosphorylation, and upregulates SERCA2a expression in cardiomyocytes and in an ISO-induced heart failure rat model.\",\n      \"method\": \"siRNA knockdown, pharmacological inhibition with C33(S) and PF-7943 in neonatal rat cardiomyocytes, in vivo rat heart failure model (ISO/AAC), echocardiography, cGMP measurement, Western blot\",\n      \"journal\": \"Acta pharmacologica Sinica\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic (siRNA) and pharmacological loss-of-function with defined molecular readouts; single lab, multiple orthogonal approaches\",\n      \"pmids\": [\"28649129\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PDE9A inhibition (BAY73-6691) significantly increases gamma-globin (HBG) gene expression in K562 erythroleukaemic cells and reverses the elevated adhesive properties of sickle cell disease neutrophils, consistent with PDE9A controlling cGMP levels in haematopoietic cells.\",\n      \"method\": \"Pharmacological inhibition with BAY73-6691 in K562 cells and primary SCD neutrophils; gene expression analysis; adhesion assay\",\n      \"journal\": \"British journal of haematology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — pharmacological loss-of-function with defined cellular phenotypes; single lab, no genetic complementation\",\n      \"pmids\": [\"18564357\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PDE9A inhibition (but not PDE2A inhibition) did not alter paired-pulse facilitation (PPF) in rat hippocampal CA1 slices, indicating PDE9A does not modulate presynaptic short-term plasticity under tested conditions, in contrast to PDE2A which acts presynaptically.\",\n      \"method\": \"Paired-pulse facilitation electrophysiology in acute rat hippocampal slices with selective PDE9A inhibitors\",\n      \"journal\": \"Synapse (New York, N.Y.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — this is a NEGATIVE finding, explicitly established by direct electrophysiological assay; single lab\",\n      \"pmids\": [\"26178667\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"In zebrafish oocytes, PDE9a maintains meiotic arrest by sustaining basal cGMP levels; overexpression of pde9aa mRNA in oocytes decreased cGMP and stimulated meiotic maturation, while PDE9a inhibition (BAY736691) also stimulated maturation via a gap-junction-dependent mechanism (blocking gap junctions abolished the effect); the stimulatory effect of elevated PDE9a during LH-induced maturation operates through oocyte cGMP hydrolysis.\",\n      \"method\": \"mRNA injection into zebrafish oocytes, cGMP measurement, pharmacological inhibition with BAY736691, gap junction blocker experiments, in vitro fertilization\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain-of-function mRNA injection plus pharmacological inhibition with gap-junction epistasis; single lab, zebrafish ortholog\",\n      \"pmids\": [\"32826058\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PDE9A deficiency (Pde9a−/− mice) does not prevent chronic-hypoxic pulmonary hypertension; RV pressure, hypertrophy, and cGMP levels were not different between Pde9a−/− and wild-type mice after 3 weeks of hypoxic exposure, indicating PDE9A does not play a prominent role in the murine CH-PH model (in contrast to its established role in left ventricular pressure overload).\",\n      \"method\": \"Pde9a knockout mice, chronic hypoxia model, RV pressure measurement, cGMP quantification, VASP phosphorylation Western blot\",\n      \"journal\": \"Physiological reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — NEGATIVE finding established by clean KO with defined physiological and biochemical readouts; single lab\",\n      \"pmids\": [\"34569183\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PDE9A is a high-affinity, cGMP-specific phosphodiesterase (Km ~170 nM for cGMP) that exists in multiple alternatively spliced isoforms with distinct subcellular localizations—PDE9A1 is nuclear (via a pat7 NLS), PDE9A5 is cytoplasmic, and brain isoforms associate with membranes and nuclear fractions—and its protein level is regulated by at least two E3 ubiquitin ligases (CHIP and NEURL1) that polyubiquitinate PDE9A for autophagic or proteasomal degradation; by controlling compartment-specific cGMP pools, PDE9A modulates PKG-dependent signaling in cardiomyocytes (affecting phospholamban/SERCA2a), inhibitory processing in the cone pathway of the retina, cGMP-dependent meiotic arrest in oocytes, and haematopoietic cell function, while its inhibition is cardioprotective in left ventricular pressure overload but not in right ventricular hypoxic hypertension.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"PDE9A is a high-affinity, cGMP-specific phosphodiesterase (Km ~170 nM for cGMP) that shapes compartment-specific cGMP pools across multiple tissues [#0]. It hydrolyzes cGMP with selectivity over cAMP, lacks the allosteric cGMP-binding regulatory regions found in PDE2/5/6, and is insensitive to classic PDE inhibitors while being blocked by zaprinast; substrate discrimination at the catalytic site operates through a glutamine-switch involving Gln453 [#0, #5]. The gene is alternatively spliced into isoforms that differ only in their N-terminal extensions, and these N-termini dictate subcellular targeting: PDE9A1 is nuclear via a pat7 NLS while PDE9A5 is cytoplasmic, and brain isoforms partition between membrane and nuclear fractions in an age- and region-specific manner [#1, #2, #3]. PDE9A protein abundance is set by ubiquitin-dependent turnover through two E3 ligases—CHIP, which polyubiquitinates PDE9A for autophagic degradation, and NEURL1, which targets it for proteasomal degradation [#6, #7]. Through control of local cGMP/PKG signaling, PDE9A modulates cardiomyocyte hypertrophy via the phospholamban/SERCA2a axis [#8], inhibitory processing in the retinal cone pathway [#4], cGMP-dependent meiotic arrest in oocytes [#11], and haematopoietic cell function [#9]; its inhibition is beneficial in left ventricular pressure overload but not in chronic-hypoxic pulmonary hypertension [#8, #12].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"Established the core catalytic identity of PDE9A as the highest-affinity cGMP phosphodiesterase known, distinguishing it from other PDEs by inhibitor profile and absence of allosteric regulatory domains.\",\n      \"evidence\": \"Baculovirus expression of FLAG-tagged PDE9A with radiometric kinetics and inhibitor panel testing in vitro\",\n      \"pmids\": [\"9624146\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structural basis for cGMP selectivity resolved at this stage\", \"Physiological cGMP source and downstream effectors not addressed\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Defined the gene architecture and alternative splicing that generates isoforms differing only in N-terminal sequence, framing how a single catalytic enzyme could be diversified functionally.\",\n      \"evidence\": \"cDNA cloning, genomic sequencing and Northern blot across human and mouse\",\n      \"pmids\": [\"9856478\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of distinct N-termini not yet tested\", \"Isoform-specific expression patterns unresolved\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Showed that the spliced N-terminal extensions act as localization signals, explaining how PDE9A isoforms partition cGMP hydrolysis between nucleus and cytoplasm.\",\n      \"evidence\": \"Transfection, reciprocal subcellular fractionation/Western blot and kinetic assays in HEK293 and T cells\",\n      \"pmids\": [\"14527714\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Compartment-specific cGMP substrate pools not directly measured\", \"In vivo relevance of nuclear vs cytoplasmic targeting unestablished\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Connected PDE9A to a specific neural circuit function by showing knockout selectively alters cone-pathway ERG recovery, identifying a role in retinal inhibitory processing.\",\n      \"evidence\": \"LacZ reporter knock-in, immunofluorescence and electroretinography in PDE9A knockout mice\",\n      \"pmids\": [\"25018695\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Downstream PKG targets in amacrine/ganglion cells not identified\", \"Mechanism linking cGMP to inhibitory processing not resolved\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Implicated PDE9A in haematopoietic cell biology by showing inhibition induces gamma-globin and reverses sickle-cell neutrophil adhesion.\",\n      \"evidence\": \"Pharmacological inhibition (BAY73-6691) in K562 cells and SCD neutrophils with gene expression and adhesion assays\",\n      \"pmids\": [\"18564357\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No genetic confirmation of target specificity\", \"cGMP effector pathway in these cells undefined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Distinguished PDE9A from PDE2A in synaptic physiology by demonstrating PDE9A inhibition does not affect presynaptic short-term plasticity.\",\n      \"evidence\": \"Paired-pulse facilitation electrophysiology in rat hippocampal slices with selective inhibitors\",\n      \"pmids\": [\"26178667\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Negative result; postsynaptic or other plasticity roles not excluded\", \"Single lab, conditions-limited\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Linked PDE9A to cardiac hypertrophy through the cGMP–PKG–phospholamban/SERCA2a axis, establishing a cardioprotective rationale for inhibition.\",\n      \"evidence\": \"siRNA knockdown and pharmacological inhibition in cardiomyocytes plus an in vivo rat heart failure model with cGMP and Western blot readouts\",\n      \"pmids\": [\"28649129\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Which PDE9A isoform mediates the cardiac pool not defined\", \"Direct PKG-PDE9A spatial coupling not shown\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Resolved isoform-specific and brain-region-specific subcellular distribution, showing PDE9A compartmentalization changes across neurodevelopment and aging.\",\n      \"evidence\": \"Subcellular fractionation of mouse and human brain with isoform-specific detection and developmental mRNA profiling\",\n      \"pmids\": [\"29505961\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional output of novel brain isoforms unknown\", \"Membrane-association mechanism not defined\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Extended PDE9A substrate scope to the non-canonical cyclic nucleotide cUMP and provided a structural glutamine-switch explanation for nucleotide selectivity.\",\n      \"evidence\": \"HPLC-tandem MS kinetic assays with computational docking to the PDE9A crystal structure\",\n      \"pmids\": [\"30443663\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological role of cUMP hydrolysis unestablished\", \"Docking model not validated by mutagenesis\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defined a reproductive function for PDE9A in maintaining oocyte meiotic arrest through gap-junction-dependent cGMP control.\",\n      \"evidence\": \"mRNA injection and pharmacological inhibition in zebrafish oocytes with cGMP measurement and gap-junction epistasis\",\n      \"pmids\": [\"32826058\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mammalian oocyte relevance not tested\", \"Source of the cGMP pool not pinpointed\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Delineated the limits of PDE9A's cardiopulmonary role by showing knockout does not prevent chronic-hypoxic pulmonary hypertension, contrasting with left ventricular pressure overload.\",\n      \"evidence\": \"Pde9a knockout mice in a chronic hypoxia model with RV pressure, cGMP and VASP phosphorylation readouts\",\n      \"pmids\": [\"34569183\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Negative result; mechanism of context-dependence unexplained\", \"Compensatory PDE activity not assessed\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identified ubiquitin-dependent control of PDE9A abundance by two distinct E3 ligases, defining how PDE9A protein levels—and thus cGMP/PKG signaling—are set, with therapeutic relevance in CHIP-ataxia and bladder cancer.\",\n      \"evidence\": \"Co-IP, polyubiquitination assays, RING-domain mutants, MG-132 and pharmacological/viral rescue across a rodent ataxia model and bladder cancer cell lines\",\n      \"pmids\": [\"39806097\", \"40442542\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CHIP and NEURL1 target the same isoforms or compartments unknown\", \"Crosstalk between autophagic and proteasomal routes not resolved\", \"PKG/PKA phosphorylation feedback on degradation mapped only in CHIP context\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unknown how the distinct localized cGMP pools generated by individual PDE9A isoforms are coupled to specific PKG effectors across tissues, and how ubiquitin-dependent turnover is coordinated with this spatial control.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No isoform-resolved mapping of cGMP microdomains to effectors\", \"Integration of E3-ligase regulation with subcellular targeting unexplored\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 2, 5]},\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [0, 5]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [2, 3]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [2]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [3]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0162582\", \"supporting_discovery_ids\": []}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"STUB1\", \"NEURL1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":5,"faith_pct":100.0}}